Sheaff M - Search Results

1

Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.

Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S, Steele J, Wells P, Shiu CF, Kuo CL, Feng X, Johnston A, Bomalaski J, Ellis S, Grantham M, Sheaff M. Szlosarek PW, et al. Among authors: sheaff m. Cancer Med. 2021 Oct;10(19):6642-6652. doi: 10.1002/cam4.4196. Epub 2021 Aug 12. Cancer Med. 2021. PMID: 34382365 Free PMC article. Clinical Trial.

2

Membranous nephropathy resolving with treatment of bronchial carcinoid tumor.

Ashman N, Steele JP, Sheaff M, Rudd RM, Onwubalili J. Ashman N, et al. Among authors: sheaff m. Am J Kidney Dis. 2000 Sep;36(3):E15. doi: 10.1053/ajkd.2000.16214. Am J Kidney Dis. 2000. PMID: 10977808

3

Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R. Fennell DA, et al. J Clin Oncol. 2005 Jan 1;23(1):184-9. doi: 10.1200/JCO.2005.07.050. J Clin Oncol. 2005. PMID: 15625372

4

Prognostic factors in mesothelioma.

Steele JP, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT, Shamash J, Rudd RM. Steele JP, et al. Among authors: sheaff mt. Lung Cancer. 2005 Jul;49 Suppl 1:S49-52. doi: 10.1016/j.lungcan.2005.03.009. Lung Cancer. 2005. PMID: 15894403

5

Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).

Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Klabatsa A, et al. Among authors: sheaff mt. Lung Cancer. 2006 Jan;51(1):53-9. doi: 10.1016/j.lungcan.2005.07.010. Epub 2005 Sep 16. Lung Cancer. 2006. PMID: 16169121

6

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. Szlosarek PW, et al. Among authors: sheaff m. Clin Cancer Res. 2006 Dec 1;12(23):7126-31. doi: 10.1158/1078-0432.CCR-06-1101. Clin Cancer Res. 2006. PMID: 17145837

7

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Fennell DA, et al. Among authors: sheaff mt. Cancer. 2007 Jan 1;109(1):93-9. doi: 10.1002/cncr.22366. Cancer. 2007. PMID: 17146783 Free article.

8

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.

Fennell DA, Steele JP, Shamash J, Slater SE, Sheaff MT, Wells P, Rudd RM, Stebbing J. Fennell DA, et al. Among authors: sheaff mt. Int J Cancer. 2007 Dec 1;121(11):2575-7. doi: 10.1002/ijc.22984. Int J Cancer. 2007. PMID: 17680556 Free article. Clinical Trial.

9

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. Stebbing J, et al. Among authors: sheaff mt. Lung Cancer. 2009 Jan;63(1):94-7. doi: 10.1016/j.lungcan.2008.04.001. Epub 2008 May 16. Lung Cancer. 2009. PMID: 18486273

10

A patient with CLL and a dry cough.

Tsitsikas DA, Vinicombe S, Sheaff M, Ellis S, Rizvi H, Manuel R, Agrawal SG. Tsitsikas DA, et al. Among authors: sheaff m. BMJ. 2010 Jun 30;340:c3051. doi: 10.1136/bmj.c3051. BMJ. 2010. PMID: 20591962 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page